Antonio Cigliola, MD

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.